What’s the current market cap for AtriCure stock?

AtriCure (ATRC) has a market cap of $1.4bn as of June 16, 2026.

What is the P/E ratio for AtriCure stock?

The price to earnings (P/E) ratio for AtriCure (ATRC) stock is 0 as of June 16, 2026.

Does AtriCure stock pay dividends?

No, AtriCure (ATRC) stock does not pay dividends to its shareholders as of June 16, 2026.

When is the next AtriCure dividend payment date?

AtriCure (ATRC) stock does not pay dividends to its shareholders.

What is the beta indicator for AtriCure?

AtriCure (ATRC) has a beta rating of 1.28. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy AtriCure stock | $ATRC Share Price

13:30

15:10

16:45

18:25

20:00

About AtriCure

AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation, Pacing and Sensing, and others. Geographically, it generates a majority of its revenue from the United States. Cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures.

Ticker

$ATRC

Sector

Health

Primary listing

NASDAQ

Employees

1,350

Headquarters

Mason, United States

Website

www.atricure.com

AtriCure Metrics

BasicAdvanced

$1.4bn

-$0.10

1.28

What the Analysts think about AtriCure

Analyst ratings (Buy, Hold, Sell) for AtriCure stock.

Bulls say / Bears say

AtriCure reported first quarter 2026 revenue of $141.2 million, up 14.3% year-over-year, supported by 14.9% growth in U.S. sales and 11.5% international growth.

Management forecasts 12–14% organic revenue growth in 2026, driven by new product launches and greater use of existing devices.

The company received CE Mark certification under EU MDR for AtriClip FLEX-Mini and PRO-Mini, setting up planned European launches later in 2026 to boost international revenue.

The hybrid AFib segment is still under pressure due to increased use of pulsed field ablation, which could limit growth for minimally invasive procedures even though other areas are performing well.

Net income for Q1 2026 was just $0.1 million, resulting in a minimal net margin and highlighting weak profitability despite strong revenue growth.

Shares are trading at approximately 152 times forecast earnings, resulting in a high valuation that allows little margin for error.

Data summarised monthly by Lightyear AI. Last updated on 24 May 2026.

AtriCure Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

AtriCure Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $ATRC

Capital at risk

Market open

Upcoming events

No upcoming events